The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Prostate Cancer Diagnostics-Global Market Insights and Sales Trends 2025
Synopsis
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
The global Prostate Cancer Diagnostics market size is expected to reach US$ 22860 million by 2029, growing at a CAGR of 7.8% from 2023 to 2029. The market is mainly driven by the significant applications of Prostate Cancer Diagnostics in various end use industries. The expanding demands from the Age Below 55, Age 55-75 and Age Above 75,, are propelling Prostate Cancer Diagnostics market. Tumor Biomarker Tests, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Imaging segment is estimated at % CAGR for the next seven-year period.
Market competition is intense. Genomic Health, Abbott, OPKO, Siemens Healthcare, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. Those key players got about 4% market shares. North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49%. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Prostate Cancer Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Prostate Cancer Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Prostate Cancer Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Prostate Cancer Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Prostate Cancer Diagnostics covered in this report include OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health and DiaSorin, etc.
The global Prostate Cancer Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
OPKO
Genomic Health
Abbott
Beckman Coulter
Siemens Healthcare
bioMeriux
Roche
MDx Health
DiaSorin
Myriad Genetics
Ambry Genetics
Global Prostate Cancer Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Prostate Cancer Diagnostics market, Segment by Type:
Tumor Biomarker Tests
Imaging
Biopsy
Other
Global Prostate Cancer Diagnostics market, by Application
Age Below 55
Age 55-75
Age Above 75
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Prostate Cancer Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
The global Prostate Cancer Diagnostics market size is expected to reach US$ 22860 million by 2029, growing at a CAGR of 7.8% from 2023 to 2029. The market is mainly driven by the significant applications of Prostate Cancer Diagnostics in various end use industries. The expanding demands from the Age Below 55, Age 55-75 and Age Above 75,, are propelling Prostate Cancer Diagnostics market. Tumor Biomarker Tests, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Imaging segment is estimated at % CAGR for the next seven-year period.
Market competition is intense. Genomic Health, Abbott, OPKO, Siemens Healthcare, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. Those key players got about 4% market shares. North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49%. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Prostate Cancer Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Prostate Cancer Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Prostate Cancer Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Prostate Cancer Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Prostate Cancer Diagnostics covered in this report include OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health and DiaSorin, etc.
The global Prostate Cancer Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
OPKO
Genomic Health
Abbott
Beckman Coulter
Siemens Healthcare
bioMeriux
Roche
MDx Health
DiaSorin
Myriad Genetics
Ambry Genetics
Global Prostate Cancer Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Prostate Cancer Diagnostics market, Segment by Type:
Tumor Biomarker Tests
Imaging
Biopsy
Other
Global Prostate Cancer Diagnostics market, by Application
Age Below 55
Age 55-75
Age Above 75
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Prostate Cancer Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Prostate Cancer Diagnostics
1.1 Prostate Cancer Diagnostics Market Overview
1.1.1 Prostate Cancer Diagnostics Product Scope
1.1.2 Prostate Cancer Diagnostics Market Status and Outlook
1.2 Global Prostate Cancer Diagnostics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Prostate Cancer Diagnostics Market Size by Region (2018-2029)
1.4 Global Prostate Cancer Diagnostics Historic Market Size by Region (2018-2023)
1.5 Global Prostate Cancer Diagnostics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Prostate Cancer Diagnostics Market Size (2018-2029)
1.6.1 North America Prostate Cancer Diagnostics Market Size (2018-2029)
1.6.2 Europe Prostate Cancer Diagnostics Market Size (2018-2029)
1.6.3 Asia-Pacific Prostate Cancer Diagnostics Market Size (2018-2029)
1.6.4 Latin America Prostate Cancer Diagnostics Market Size (2018-2029)
1.6.5 Middle East & Africa Prostate Cancer Diagnostics Market Size (2018-2029)
2 Prostate Cancer Diagnostics Market by Type
2.1 Introduction
2.1.1 Tumor Biomarker Tests
2.1.2 Imaging
2.1.3 Biopsy
2.1.4 Other
2.2 Global Prostate Cancer Diagnostics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Prostate Cancer Diagnostics Historic Market Size by Type (2018-2023)
2.2.2 Global Prostate Cancer Diagnostics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Prostate Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Prostate Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Prostate Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Prostate Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Prostate Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
3 Prostate Cancer Diagnostics Market Overview by Application
3.1 Introduction
3.1.1 Age Below 55
3.1.2 Age 55-75
3.1.3 Age Above 75
3.2 Global Prostate Cancer Diagnostics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Prostate Cancer Diagnostics Historic Market Size by Application (2018-2023)
3.2.2 Global Prostate Cancer Diagnostics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Prostate Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Prostate Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Prostate Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Prostate Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Prostate Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
4 Prostate Cancer Diagnostics Competition Analysis by Players
4.1 Global Prostate Cancer Diagnostics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Prostate Cancer Diagnostics as of 2022)
4.3 Date of Key Players Enter into Prostate Cancer Diagnostics Market
4.4 Global Top Players Prostate Cancer Diagnostics Headquarters and Area Served
4.5 Key Players Prostate Cancer Diagnostics Product Solution and Service
4.6 Competitive Status
4.6.1 Prostate Cancer Diagnostics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 OPKO
5.1.1 OPKO Profile
5.1.2 OPKO Main Business
5.1.3 OPKO Prostate Cancer Diagnostics Products, Services and Solutions
5.1.4 OPKO Prostate Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.1.5 OPKO Recent Developments
5.2 Genomic Health
5.2.1 Genomic Health Profile
5.2.2 Genomic Health Main Business
5.2.3 Genomic Health Prostate Cancer Diagnostics Products, Services and Solutions
5.2.4 Genomic Health Prostate Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.2.5 Genomic Health Recent Developments
5.3 Abbott
5.3.1 Abbott Profile
5.3.2 Abbott Main Business
5.3.3 Abbott Prostate Cancer Diagnostics Products, Services and Solutions
5.3.4 Abbott Prostate Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.3.5 Beckman Coulter Recent Developments
5.4 Beckman Coulter
5.4.1 Beckman Coulter Profile
5.4.2 Beckman Coulter Main Business
5.4.3 Beckman Coulter Prostate Cancer Diagnostics Products, Services and Solutions
5.4.4 Beckman Coulter Prostate Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.4.5 Beckman Coulter Recent Developments
5.5 Siemens Healthcare
5.5.1 Siemens Healthcare Profile
5.5.2 Siemens Healthcare Main Business
5.5.3 Siemens Healthcare Prostate Cancer Diagnostics Products, Services and Solutions
5.5.4 Siemens Healthcare Prostate Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.5.5 Siemens Healthcare Recent Developments
5.6 bioMeriux
5.6.1 bioMeriux Profile
5.6.2 bioMeriux Main Business
5.6.3 bioMeriux Prostate Cancer Diagnostics Products, Services and Solutions
5.6.4 bioMeriux Prostate Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.6.5 bioMeriux Recent Developments
5.7 Roche
5.7.1 Roche Profile
5.7.2 Roche Main Business
5.7.3 Roche Prostate Cancer Diagnostics Products, Services and Solutions
5.7.4 Roche Prostate Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.7.5 Roche Recent Developments
5.8 MDx Health
5.8.1 MDx Health Profile
5.8.2 MDx Health Main Business
5.8.3 MDx Health Prostate Cancer Diagnostics Products, Services and Solutions
5.8.4 MDx Health Prostate Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.8.5 MDx Health Recent Developments
5.9 DiaSorin
5.9.1 DiaSorin Profile
5.9.2 DiaSorin Main Business
5.9.3 DiaSorin Prostate Cancer Diagnostics Products, Services and Solutions
5.9.4 DiaSorin Prostate Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.9.5 DiaSorin Recent Developments
5.10 Myriad Genetics
5.10.1 Myriad Genetics Profile
5.10.2 Myriad Genetics Main Business
5.10.3 Myriad Genetics Prostate Cancer Diagnostics Products, Services and Solutions
5.10.4 Myriad Genetics Prostate Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.10.5 Myriad Genetics Recent Developments
5.11 Ambry Genetics
5.11.1 Ambry Genetics Profile
5.11.2 Ambry Genetics Main Business
5.11.3 Ambry Genetics Prostate Cancer Diagnostics Products, Services and Solutions
5.11.4 Ambry Genetics Prostate Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.11.5 Ambry Genetics Recent Developments
6 North America
6.1 North America Prostate Cancer Diagnostics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Prostate Cancer Diagnostics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Prostate Cancer Diagnostics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Prostate Cancer Diagnostics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Prostate Cancer Diagnostics Market Dynamics
11.1 Prostate Cancer Diagnostics Industry Trends
11.2 Prostate Cancer Diagnostics Market Drivers
11.3 Prostate Cancer Diagnostics Market Challenges
11.4 Prostate Cancer Diagnostics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
